Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan Berlin

Showing results (111-120 of 148) with videos related to

Pageof 15
Sort By:
The Oncologist|March 8, 2018
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced CancersAnthony Tolcher, Keith Flaherty, Geoffrey I Shapiro, et al.
The Oncologist|February 25, 2021
Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal CancerIbrahim Halil Sahin, Subir Goyal, Yoanna Pumpalova, et al.
The Oncologist|August 20, 2020
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I StudyJohanna Bendell, Sunil Sharma, Manish R Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2021
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline UpdateNancy N Baxter, Erin B Kennedy, Emily Bergsland, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2025
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancerChangsong Qi, Lin Shen, Thierry Andre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatmentPhilip A Philip, Margaret Mooney, Deborah Jaffe, et al.
The New England Journal of Medicine|March 14, 2008
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactoseChristine H Chung, Beloo Mirakhur, Emily Chan, et al.
International Journal of Radiation Oncology, Biology, Physics|May 26, 2024
Executive Summary of the American Radium Society on Appropriate Use Criteria for Nonoperative Management of Rectal Adenocarcinoma: Systematic Review and GuidelinesChristopher J Anker, Leila T Tchelebi, J Eva Selfridge, et al.
The Oncologist|January 21, 2016
Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal CancerLawrence Leichman, Susan Groshen, Bert H O'Neil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2018
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I StudyManish A Shah, Alexander Starodub, Sunil Sharma, et al.
Pageof 15

Showing results (111-120 of 148) with videos related to

Sort By:
Pageof 15
The Oncologist|March 8, 2018
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced CancersAnthony Tolcher, Keith Flaherty, Geoffrey I Shapiro, et al.
The Oncologist|February 25, 2021
Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal CancerIbrahim Halil Sahin, Subir Goyal, Yoanna Pumpalova, et al.
The Oncologist|August 20, 2020
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I StudyJohanna Bendell, Sunil Sharma, Manish R Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2021
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline UpdateNancy N Baxter, Erin B Kennedy, Emily Bergsland, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2025
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancerChangsong Qi, Lin Shen, Thierry Andre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatmentPhilip A Philip, Margaret Mooney, Deborah Jaffe, et al.
The New England Journal of Medicine|March 14, 2008
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactoseChristine H Chung, Beloo Mirakhur, Emily Chan, et al.
International Journal of Radiation Oncology, Biology, Physics|May 26, 2024
Executive Summary of the American Radium Society on Appropriate Use Criteria for Nonoperative Management of Rectal Adenocarcinoma: Systematic Review and GuidelinesChristopher J Anker, Leila T Tchelebi, J Eva Selfridge, et al.
The Oncologist|January 21, 2016
Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal CancerLawrence Leichman, Susan Groshen, Bert H O'Neil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 26, 2018
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I StudyManish A Shah, Alexander Starodub, Sunil Sharma, et al.
Pageof 15